Company intelligence / Profile preview

Augusta Oncology

Augusta, Georgia, United States

Ownership: Private
Employees: ~150
Development stage: Other

Overview

Augusta Oncology is a comprehensive independent oncology and hematology practice based in Augusta, Georgia. The center provides a wide range of services including chemotherapy, immunotherapy, and specialized treatments for various forms of cancer and blood disorders. As a community-based provider, they offer patients access to advanced clinical trials and personalized treatment plans, integrating diagnostic imaging and an in-house pharmacy to streamline patient care. The practice is recognized for its patient-centered approach, focusing on both the medical and emotional needs of individuals undergoing cancer treatment.

Therapeutic areas: Oncology
Modalities: Small moleculeMonoclonal antibodyChemotherapyImmunotherapyHormone therapy
Industry: Non-Academic Healthcare

Partnerships

American Oncology Network

Beyond the preview

Go deeper on Augusta Oncology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Augusta Oncology.

Explore the full profile